HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

Key Takeaways

• Management presenting at Oppenheimer MedTech conference.
• CEO joins ROTH panel on healthy aging technologies.
• HeartBeam demos FDA‑cleared system at ACC.26.
• Prototype 12‑lead ECG patch showcased to physicians.
• Investor meetings aim to boost capital and partnerships.

Summary

HeartBeam Inc. announced that its executive team will attend three major investor and industry conferences in March 2026, including Oppenheimer’s virtual MedTech summit, the ROTH conference, and the American College of Cardiology’s ACC.26. The CEO and CFO will present a webcast and hold one‑on‑one investor meetings at Oppenheimer and ROTH, while the CEO, founder, and CCO will exhibit the FDA‑cleared HeartBeam System and a working prototype of a 12‑lead ECG extended‑wear patch at ACC.26. These appearances aim to provide updates on the company’s commercial launch and to showcase its emerging 12‑lead ECG technology to potential partners and investors.

Pulse Analysis

Remote cardiac monitoring is accelerating as hospitals seek to reduce admissions and patients demand continuous insight. HeartBeam’s 3‑D ECG platform, which captures signals from three non‑coplanar axes and synthesizes a full 12‑lead trace, addresses a long‑standing gap between wearable devices and clinical diagnostics. The company’s FDA clearance for arrhythmia assessment in late 2024, followed by software clearance in 2025, validates the technology and positions it for rapid adoption in ambulatory care, tele‑health, and preventive cardiology, and integration with electronic health records, enabling seamless data flow for clinicians.

By appearing at Oppenheimer’s virtual MedTech summit, the ROTH conference, and ACC.26, HeartBeam’s leadership is executing a classic roadshow to amplify visibility among institutional investors and strategic partners. The webcast and one‑on‑one meetings provide a forum to detail the commercial launch timeline, pricing strategy, and projected revenue from the cleared HeartBeam System. Demonstrating a working prototype of a 12‑lead ECG extended‑wear patch at ACC.26 further signals the company’s pipeline depth and its intent to expand the platform beyond current indications, attracting interest from device manufacturers and health systems, and explore co‑development opportunities with major OEMs.

The upcoming investor engagements come at a pivotal moment as the cardiac wearables market is projected to exceed $5 billion by 2028, driven by aging populations and reimbursement reforms. HeartBeam’s patented 3‑D sensor suite and its ability to generate clinical‑grade 12‑lead data could differentiate it from competitors that only offer single‑lead or limited‑lead solutions. Successful capital raises or partnership deals announced at these conferences would accelerate scale‑up of manufacturing, support regulatory submissions for the patch, and potentially unlock new revenue streams in chronic disease management. Furthermore, the data richness of a 12‑lead patch could fuel AI‑driven risk stratification tools.